Therapeutic Strategy Lead, Rare Disease
Juliane provides strategic support for the development of patient-focused Phase I-IV rare disease trials and is passionate about advancing rare disease clinical research. Juliane innovates study solutions by combining her therapeutic and operational expertise to make clinical studies more accessible to patients and non-traditional investigators.
Submit an RFP. Ask a Question
Juliane K. Mills, MS, MPH, has worked in clinical research for more than 23 years, providing significant scientific and strategic design input as a subject matter expert for Phase I-IV rare disease trials and real-world studies. At Worldwide, Juliane provides operational strategies that are efficient and effective for delivering rare disease trials while being accessible to patients, caregivers, and families. She also leverages her experience supporting product registries, retrospective chart reviews, health economics and outcomes research (HEOR) studies, and compassionate use/expanded access programs.
Juliane has held positions on both the sponsor and CRO side of clinical development, providing operational services and developing trial and patient-facing materials in various therapeutic areas. Additionally, she has held roles in project management, overseeing the operational delivery of studies in epidemiology, and in risk management, where she supervised the day-to-day activities for the largest post-marketing safety program in the US.
In addition to her work in clinical development, prior to joining Worldwide, Juliane’s dedication to enabling rare disease communities to be more active partners in clinical research led her to the Chan Zuckerberg Initiative Foundation. There, she trained US-based patient-led rare disease organizations to build sustainable research capacity to find treatments and cures for their communities.
Juliane holds both a Master of Public Health and a Master of Science in scientific communication from Drexel University.